Cancer Epidemiology最新文献

{"title":"Cardiovascular disease as a contributing cause of cancer mortality: A population-based analysis of United States death certificate data (1999–2020)","authors":"Sanchit Mehta ,&nbsp;Lovy Arora ,&nbsp;Netra Agarwal ,&nbsp;Asha Khubchandani","doi":"10.1016/j.canep.2026.102991","DOIUrl":"10.1016/j.canep.2026.102991","url":null,"abstract":"<div><h3>Background</h3><div>Emerging evidence suggests a complex bidirectional relationship between cardiovascular disease (CVD) and cancer. However, population-level data characterizing the burden of cardiovascular comorbidities at the time of cancer-attributable death remains limited. We analyzed the association between the presence of cardiovascular disease on death certificates and cancer mortality patterns across demographic groups using national mortality data from 1999 to 2020.</div></div><div><h3>Methods</h3><div>Using CDC WONDER multiple cause-of-death data, we analyzed records of adults ≥ 18 years with cancer as the underlying cause of death. CVD comorbidity was defined as any cardiovascular condition (ICD-10 I00-I99) listed as a contributing cause. We calculated age-adjusted mortality rates (AAMR) per 100,000 population and rate ratios, stratified by demographics and cancer types.</div></div><div><h3>Results</h3><div>Among 13,847,293 cancer deaths, 4521,847 (32.6 %) had cardiovascular disease listed as a contributing cause. The overall AAMR for cancer deaths with CVD was 47.75 per 100,000 (95 % CI: 47.66–47.85). Males showed higher rates than females (62.26 vs 37.22 per 100,000, rate ratio 1.67). Non-Hispanic Black populations had the highest burden (57.10 per 100,000), while Asian/Pacific Islander populations had the lowest (30.80 per 100,000). For lung cancer, mortality rates were substantially higher when CVD was present, with rate ratios ranging from 1.70 to 2.43; however, this association is likely attributable to profound unmeasured confounding by shared risk factors such as smoking.</div></div><div><h3>Conclusions</h3><div>Cardiovascular disease is listed as a contributing factor in nearly one-third of all cancer deaths, with distinct demographic patterns. These findings highlight the significant burden of cardiovascular comorbidities documented on death certificates at the end of life for cancer patients.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 102991"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146024976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Normalized breast cancer survival outcomes in U.S. tumor registries","authors":"Tori C. Nierenberg ,&nbsp;Kerri-Anne Crowell ,&nbsp;Samantha M. Thomas ,&nbsp;Kelley Chan ,&nbsp;Rachel A. Greenup ,&nbsp;Jennifer K. Plichta","doi":"10.1016/j.canep.2026.103015","DOIUrl":"10.1016/j.canep.2026.103015","url":null,"abstract":"<div><h3>Background</h3><div>This study normalized the National Cancer Database (NCDB) and Surveillance, Epidemiology, End Results Program (SEER) populations to mirror the USCS population and examined survival outcomes in breast cancer following normalization.</div></div><div><h3>Methods</h3><div>Patients diagnosed with stage I-IV breast cancer (2010–2018) were selected from the NCDB and SEER. Rates obtained from the USCS were used to normalize the NCDB and SEER cohorts, using patient weighted frequencies for variables (age, sex, race/ethnicity, etc). Overall survival was estimated using the Kaplan-Meier method before and after normalization.</div></div><div><h3>Results</h3><div>The USCS included 2473,739 patients, the NCDB 1441,556, and SEER 504,938. There were minimal differences between the cohorts based on age or sex. There were notable differences in the racial/ethnic composition (Hispanic: USCS 8.3 %, NCDB 5.9 %, SEER 11.7 %; p &lt; 0.001). There were minimal differences in tumor biomarkers, but significant differences in extent of disease (local: USCS 66.1 %, NCDB 80.2 %, SEER 68.4 %; distant: USCS 6 %, NCDB 3.9 %, SEER 3.9 %; p &lt; 0.001). Variables that were similar without weighting (age, sex, tumor biomarkers), had similar OS after weighting. However, when the NCDB and SEER were weighted by stage, HR status and race/ethnicity combined, slight changes were seen in 5-year OS (NCDB regional: unweighted 76.8 % vs weighted 77.0 %, SEER regional: unweighted 79.7 % vs weighted 78.5 %; p &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>US tumor registries provide data for a large sampling of breast cancer patients. Despite significant differences in case coverage based on race/ethnicity and stage, OS remained similar following normalization to the USCS, suggesting that analyses using these data sets may be generalizable to the population.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 103015"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146173804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demographic and prognostic indicators of Adenoid cystic carcinoma in the head and neck: A National Cancer Database analysis","authors":"Jiayi Wang ,&nbsp;Joel Dumonsau ,&nbsp;Nicole Grossmann ,&nbsp;Peter Silberstein ,&nbsp;Rahul Varman ,&nbsp;Marco DiBlasi","doi":"10.1016/j.canep.2026.103022","DOIUrl":"10.1016/j.canep.2026.103022","url":null,"abstract":"<div><h3>Background</h3><div>Adenoid cystic carcinoma (ACC) is a rare malignancy comprising just 1 % of all head and neck malignancies. To date, there are no National Cancer Database (NCDB) studies evaluating the demographic and prognostic factors of ACC of the head and neck. Existing studies have only utilized single-institution cohorts, other databases, and narrowly defined populations, resulting in a fragmented view. This study aims to address this by providing an NCDB analysis of all patients with ACC in the head and neck.</div></div><div><h3>Methods</h3><div>Utilizing retrospective 2004–2021 NCDB data, this study analyzed several variables including patient demographics, prognostic factors, and treatment modalities. Kaplan-Meier survival curves were plotted for overall survival, Cox Regression Models were utilized to assess hazard ratios (HRs), and binomial regression for surgical likelihood.</div></div><div><h3>Results</h3><div>ACC was most frequently located in the major salivary glands (45.2 %). The mean age at diagnosis was 58.75 years. Surgical intervention significantly improved survival, with hazard ratios ranging from 0.302 to 0.451 compared to no surgery. Overall, 69.8 % of patients received surgery. Factors associated with lower surgical likelihood included higher Charlson-Deyo scores, uninsured status, and older age. Tumor site influenced outcomes: surgically accessible sites such as the gums and oral cavity were associated with improved survival (HR 0.875), while less accessible sites like the nasopharynx and pharynx had worse outcomes (HR 1.868 and 1.123, respectively).</div></div><div><h3>Conclusion</h3><div>Surgical treatment confers a significant survival advantage in head and neck ACC. Disparities in surgical receipt based on insurance status, comorbidities, age, and tumor location highlight the need for strategies to improve equitable access to care.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 103022"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146173884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Historical parallels between harms of tobacco and e-cigarettes.","authors":"Freddy Sitas, Bernard Stewart","doi":"10.1016/j.canep.2025.102941","DOIUrl":"https://doi.org/10.1016/j.canep.2025.102941","url":null,"abstract":"","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":" ","pages":"102941"},"PeriodicalIF":2.3,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146215034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of metformin exposure on colorectal cancer incidence according to tumor sidedness","authors":"Yehudit Peerless ,&nbsp;Gal Strauss ,&nbsp;Ofer Margalit ,&nbsp;Einat Shacham-Shmueli ,&nbsp;Yu-Xiao Yang ,&nbsp;Ben Boursi","doi":"10.1016/j.canep.2025.102983","DOIUrl":"10.1016/j.canep.2025.102983","url":null,"abstract":"<div><h3>Background</h3><div>Colorectal cancer (CRC) is a major cause of cancer-related morbidity and mortality. Tumor sidedness influences treatment decisions for metastatic disease due to differences in biology and therapeutic response. Metformin, an anti-diabetic medication, may reduce CRC risk. This study aims to evaluate the relationship between metformin exposure and CRC risk based on tumor-sidedness.</div></div><div><h3>Methods</h3><div>A nested case-control study was conducted using the Veterans Administration (VA) database (1999–2020). The cohort included individuals with diabetes mellitus and at least 3 years of follow-up. CRC cases were identified and classified by tumor sidedness. Controls were selected via incidence-density sampling, matched on age, sex, index-date, and first VA encounter. Exposure of interest was cumulative metformin use prior to the index-date. Conditional logistic regression was used to estimate adjusted odds-ratios (ORs) and 95 % confidence intervals (CIs). The analysis was adjusted for race, BMI, smoking, aspirin, statins, and other anti-diabetic medications.</div></div><div><h3>Results</h3><div>The study included 31,078 CRC cases and 310,621 matched controls among diabetic individuals. Metformin exposure showed no effect on right-sided CRC incidence (adjusted OR 1.03, 95 %CI 0.92–1.16 for 1–3 years; 0.96, 95 %CI 0.83–1.12 for 3–5 years). In contrast, in patients with left-sided CRC metformin use was associated with a reduced risk of CRC (adjusted OR 0.90, 95 %CI 0.82–0.98 for 1–3 years; 0.87, 95 %CI 0.77–0.98 for 3–5 years).</div></div><div><h3>Conclusions</h3><div>Metformin was associated with a decrease in the incidence of left-sided CRC. These results suggest the influence of tumor sidedness, not only on treatment effect, but on prevention strategies as well.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"100 ","pages":"Article 102983"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden and determinants of benign prostate hyperplasia in Africa: Systematic review and meta-analysis","authors":"Kedir Seid ,&nbsp;Abel Tibebu Goshu ,&nbsp;Sintayehu Samuel Lorato ,&nbsp;Mitiku Desalegn ,&nbsp;Kelemu Abebe Gelaw ,&nbsp;Yohannes Godie Ashebir ,&nbsp;Olyad Kuma Getahun ,&nbsp;Gebeyehu Lakew ,&nbsp;Mathewos Mekonnen Gemmechu ,&nbsp;Tiruye Menshaw Tiruneh ,&nbsp;Yibeltal Assefa Atalay ,&nbsp;Amlaku Nigusie Yirsaw ,&nbsp;Eyob Ketema Bogale ,&nbsp;Natnael Atnafu Gebeyehu ,&nbsp;Tewodros Shitemaw Tekoye ,&nbsp;Genanew Kassie Getahun","doi":"10.1016/j.canep.2025.102972","DOIUrl":"10.1016/j.canep.2025.102972","url":null,"abstract":"<div><h3>Objective</h3><div>To determine the prevalence and determinants of benign prostate hyperplasia in Africa via a meta-analysis.</div></div><div><h3>Methods</h3><div>This report was presented according to the Preferred Reporting Items for Systematic Review and Meta-Analyses checklist. Thirteen articles were searched via PubMed/MEDLINE, EMBASE, Scopus, Google Scholar, Science Direct, and African Journal Online. Data were extracted via Microsoft Excel and exported to STATA 17 for analysis. The data were analyzed via the random effects model. The heterogeneity of the studies was assessed by Cochran’s Q test and I² statistics. Publication bias was detected via funnel plots and Egger’s test.</div></div><div><h3>Result</h3><div>In 13 studies conducted in Africa, with a sample size of 5619 people between 2011 and 2024, the pooled prevalence of benign prostate hyperplasia was 44 % (95 % CI 31 %-57 %) in Africa. According to the subgroup analysis, the pooled prevalence was greater in studies published from 2011--2018 (56 % (95 % CI: 38--73)) than in those published from 2019--2024 (34 %). The pooled prevalence rates were also greater in those with sample sizes &gt; 500 than in those with sample sizes &lt; 500 (45 % vs 41 %). Family history of BPH (OR = 5.56; 95 % CI; 1<strong>.</strong>57, 9.55), difficulty in sexual activity (OR = 13.14; 95 % CI: 5.50, 20.77), use of traditional eye medication (OR = 2.27; 95 % CI: 1.68, 2.86), family history (OR = 4.93; 95 % CI: 3.13, 6.72) and inadequate sleeping time (OR = 2.90, 95 % CI = 2.25–3.55) were factors associated with benign prostate hyperplasia among adults.</div></div><div><h3>Conclusions</h3><div>The pooled prevalence of BPH among adults living in Africa was significant. Family history, difficulty in sexual activity and inadequate sleeping time were significantly associated with benign prostate hyperplasia. The greater burden of BPH across the country calls for efforts by health policy makers to pay attention to it.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"100 ","pages":"Article 102972"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145679753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Humidifier disinfectant exposure and lung cancer development: A propensity score matching analysis","authors":"Su Hwan Kim ,&nbsp;Sungchan Kang ,&nbsp;Sanghee Shin ,&nbsp;Jeong-In Hwang ,&nbsp;Hyungryul Lim ,&nbsp;Dong-Wook Lee ,&nbsp;Woojoo Lee ,&nbsp;Kang Hee Ha ,&nbsp;Youngmee Lee ,&nbsp;Taksoo Kim ,&nbsp;Hye-Jin Kim ,&nbsp;Kyoung-Nam Kim","doi":"10.1016/j.canep.2025.102982","DOIUrl":"10.1016/j.canep.2025.102982","url":null,"abstract":"<div><h3>Background</h3><div>Although previous animal studies suggest an association between humidifier disinfectant (HD) exposure and lung cancer, epidemiological evidence remains limited.</div></div><div><h3>Methodology</h3><div>Nationwide data from the National Health Insurance Service and survey data on the HD claimant group were used. A 1:30 propensity score matching was conducted between the HD claimant (<em>n</em> = 4567) and non-exposed groups (<em>n</em> = 153,071). Hazard ratios (HRs) and 95 % confidence intervals (CIs) were estimated using Cox proportional hazards models, incorporating a 4-year latency period.</div></div><div><h3>Results</h3><div>After matching, the incidence of lung cancer was 2.58 % in the HD claimant group and 0.55 % in the non-exposed group. In the Cox models, the HR for lung cancer in the HD claimant group was 5.71 (95 % CI: 4.70, 6.92) compared with the non-exposed group. Stratified analyses showed an HR of 12.61 (95 % CI: 8.94, 17.79) among women and 4.31 (95 % CI: 3.40, 5.47) among men. The associations also persisted in never-smokers, with an HR of 4.33 (95 % CI: 2.26, 8.30).</div></div><div><h3>Conclusions</h3><div>Exposure to HDs was associated with an increased risk of lung cancer development. Combined with in vivo and in vitro studies reporting similar associations and plausible mechanisms, the present study supports the potential carcinogenic effects of HDs on lung cancer.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"100 ","pages":"Article 102982"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between insulin-like growth factor 1, IGF-binding protein 3, and colorectal cancer","authors":"Thomas Lawler ,&nbsp;Zoe L. Walts ,&nbsp;Lauren Giurini ,&nbsp;Mark Steinwandel ,&nbsp;Wei Zheng ,&nbsp;Shaneda Warren Andersen","doi":"10.1016/j.canep.2026.102986","DOIUrl":"10.1016/j.canep.2026.102986","url":null,"abstract":"<div><h3>Background</h3><div>Higher serum insulin-like growth factor 1 (IGF-1) has been linked to colorectal cancer (CRC), with evidence supporting increased risk for colon but not rectal tumors. Few studies have included substantial numbers of non-Hispanic Black individuals, who have elevated population-level CRC risk. We investigated associations between IGF-1 and CRC in the Southern Community Cohort Study. We also report associations with IGF binding protein 3 (IGFBP-3), the primary IGF-1 transporter, and the IGF-1/IGFBP-3 ratio (a surrogate marker for biologically available IGF-1).</div></div><div><h3>Methods</h3><div>Participants with incident CRC (N = 297) were individually matched with controls (N = 604) on age, race, and sex. The majority of the cohort reports Black racial identity (75 %). Serum IGF-1 and IGFBP-3 were measured at enrollment. Logistic regression was used to estimate odds ratios (ORs) with 95 % confidence intervals (CIs) for CRC, colon and rectal cancers.</div></div><div><h3>Results</h3><div>For higher IGF-1 (tertile 3vs1), the OR for CRC was 1.45 (CI 0.95–2.21). Higher IGF-1 was associated with greater odds for colon cancer (OR 1.64, CI 1.01–2.64) but not rectal cancer (OR 0.93, CI 0.43–1.97). The associations with CRC and colon cancer were consistent among participants who fasted prior to serum draw (N = 356, CRC: OR 1.89, CI 0.95–3.78; colon cancer: OR 2.08, CI 0.96–4.51). No associations were observed for IGFBP-3 or the IGF-1/IGFBP-3 ratio in the full sample.</div></div><div><h3>Conclusion</h3><div>Higher IGF-1 was associated with increased odds for colon cancer, but not rectal cancer, among predominantly non-Hispanic Black individuals with lower socioeconomic status, consistent with findings from predominantly non-Hispanic White cohorts.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"100 ","pages":"Article 102986"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145924709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Angiotensin converting enzyme inhibitors and angiotensin receptor blockers and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) study","authors":"Azam Majidi ,&nbsp;Renhua Na ,&nbsp;Susan J. Jordan ,&nbsp;Tanya L. Ross ,&nbsp;Anna DeFazio ,&nbsp;Michael Friedlander ,&nbsp;Peter Grant ,&nbsp;Penelope M. Webb","doi":"10.1016/j.canep.2025.102961","DOIUrl":"10.1016/j.canep.2025.102961","url":null,"abstract":"<div><h3>Objective</h3><div>There is some evidence that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) might improve cancer survival, but reliable data for ovarian cancer are scarce. We evaluated this using data from the prospective Ovarian cancer Prognosis and Lifestyle (OPAL) study.</div></div><div><h3>Materials and methods</h3><div>We included 954 Australian women diagnosed between 2012 and 2015 and considered pre-diagnosis and post-diagnosis medication use and ovarian cancer survival. We used Cox proportional hazard models to estimate adjusted hazard ratios (aHR) and 95 % confidence intervals (CI) for all medication users and monotherapy users (those who used a single medication). We applied inverse probability of treatment weighting to further reduce confounding and estimated restricted mean survival time at 7 years (end of study).</div></div><div><h3>Results</h3><div>We observed a modest association between ARB use before or after diagnosis and progression-free and ovarian cancer-specific survival. Estimates were further from the null for post-diagnosis use ARB monotherapy, and when weighted for users (pre-diagnosis use aHR=0.71, 95 %CI: 0.51–0.98; post-diagnosis use aHR=0.60, 0.36–1.01 for ovarian cancer-specific survival). If real, this would translate to a 6-month increase in mean survival for ARB monotherapy. The associations were attenuated in models weighted for all women. There was little evidence of an association with ACE inhibitors.</div></div><div><h3>Conclusions</h3><div>Further evaluation in larger cohorts is required to confirm these findings. If the observed associations are confirmed, ARBs may warrant consideration as a first line hypertension treatment for women with ovarian cancer.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"100 ","pages":"Article 102961"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145555338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Socioeconomic inequalities in prostate cancer mortality: Response to recent commentary","authors":"Mohammad Hajizadeh,&nbsp;Grace Johnston","doi":"10.1016/j.canep.2025.102978","DOIUrl":"10.1016/j.canep.2025.102978","url":null,"abstract":"<div><div>This document is the authors’ response to the received comments for manuscript CANEP-D-25-00363.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"100 ","pages":"Article 102978"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145806469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}